Nyxoah Prepares for Q3 2024 Financial Results Release
Nyxoah SA (Euronext Brussels/NASDAQ: NYXH) is gearing up to unveil its financial performance for the third quarter of 2024. This announcement is set for November 6, 2024, following the market's close.
Details of the Earnings Call
The management at Nyxoah will host a conference call to review these results, starting at 10:30 PM CET/4:30 PM ET. This update is a significant moment for the company, which specializes in innovative treatments for Obstructive Sleep Apnea (OSA).
How to Access the Webcast
Investors and interested parties can access the call through the Investor Relations section of Nyxoah’s official website. For those who prefer to directly join and engage with management, a special link will be available during the call.
Directions for Participation
If you're interested in asking questions during the call, registration via a specific link is essential. After signing up, individuals will receive an email containing dial-in information and a unique access code necessary for participation. It is advisable to register at least 10 minutes ahead of the call to ensure seamless connectivity.
About Nyxoah's Mission
Nyxoah is committed to transforming sleep solutions for the millions impacted by OSA. With its flagship product, Genio®, Nyxoah has developed a breakthrough, battery-free device that utilizes hypoglossal neuromodulation to enhance patient care.
Innovations and Regulatory Milestones
Genio® has already earned European CE Mark certification since 2019, indicating its safety and effectiveness. With two successful IPOs on significant stock markets, the products developed by Nyxoah underscore their focus on clinical excellence and innovation.
Future Outlook for Nyxoah
Following positive results from significant clinical studies, including the BETTER SLEEP study, Nyxoah has successfully gained approval for expanded therapeutic indications. This positions the company competitively in the market, especially against therapies that have not shown the same results for certain patients.
Ongoing Commitment to Patients
Nyxoah is not only focused on introducing innovative devices but also ensuring these treatments meet robust clinical evidence. The outcomes from these studies emphasize the company's dedication to addressing OSA effectively.
Contact Information for Inquiries
For further information, interested parties can reach out directly to Nyxoah:
Nyxoah
Loïc Moreau, Chief Financial Officer
Email: IR@nyxoah.com
This upcoming earnings release marks an exciting milestone for Nyxoah, as it progresses in redefining patient care in the realm of obstructive sleep apnea management.
Frequently Asked Questions
What financial results will Nyxoah release?
Nyxoah will disclose its financial results for the third quarter of 2024, highlighting key metrics and achievements.
How can investors join the earnings call?
Investors can join the call through Nyxoah's Investor Relations page, with a registration link available for those wishing to ask questions.
What does Genio® offer to patients?
Genio® is a novel, battery-free device aimed at treating obstructive sleep apnea through hypoglossal neuromodulation.
When was Genio® approved?
Genio® received its European CE Mark approval in 2019, indicating its compliance with safety and efficacy standards.
Who should I contact for more information?
For inquiries, you can contact Nyxoah’s Chief Financial Officer, Loïc Moreau, at the provided email.
